Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

被引：0
|
作者：
Parekh, Krupa [1 ]
Watkins, Claire [2 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] Clarostat Consulting Ltd, Macclesfield, Cheshire, England
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 17期
关键词：
disease-modifying therapies; multiple sclerosis; network meta-analysis; relapsing multiple sclerosis;
D O I：
10.2217/cer-2021-0123
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：1265 / 1266
页数：2
相关论文
共 50 条
  • [31] Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis
    Sriwastava, Shitiz
    Kataria, Saurabh
    Srivastava, Samiksha
    Kazemlou, Shaghayegh
    Gao, Si
    Wen, Sijin
    Saber, Hamidreza
    Tripathi, Richa
    Sheikh, Zubeda
    Peterson, Sarah
    Gwinn, Ronald
    Bernitsas, Evanthia
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 360
  • [32] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [33] The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
    Branger, Pierre
    Parienti, Jean-Jacques
    Sormani, Maria Pia
    Defer, Gilles
    PLOS ONE, 2016, 11 (03):
  • [34] New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis
    Vidal-Jordana, Angela
    NEUROLOGIC CLINICS, 2018, 36 (01) : 173 - +
  • [35] Pregnancy and disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Oztekin, N. S.
    Oztekin, M. F.
    MULTIPLE SCLEROSIS, 2006, 12 : S95 - S96
  • [36] Disease modifying therapies for relapsing multiple sclerosis
    Wingerchuk, Dean M.
    Weinshenker, Brian G.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [37] Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Mouallif, Soukaina
    Thomas, Kim
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Grima, Daniel
    NEUROLOGY, 2022, 98 (18)
  • [38] COST EFFECTIVENESS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
    Mouallif, S.
    Thomas, K.
    Adlard, N. E.
    Cooney, P.
    Blanchette, F.
    Patel, B. P.
    Baharnoori, M.
    Bhan, V
    Clift, F.
    Grima, D.
    VALUE IN HEALTH, 2022, 25 (01) : S63 - S63
  • [39] Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
    Etemadifar, Masoud
    Nouri, Hosein
    Pitzalis, Maristella
    Idda, Maria Laura
    Salari, Mehri
    Baratian, Mahshid
    Mahdavi, Sepide
    Abhari, Amir Parsa
    Sedaghat, Nahad
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09): : 986 - 994
  • [40] Discontinuing disease-modifying multiple sclerosis therapies
    Krysko, Kristen
    LANCET NEUROLOGY, 2023, 22 (07): : 543 - 545
12345